Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab

Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab

Abstract The checkpoint inhibitor nivolumab is active in patients with metastatic melanoma who have failed ipilimumab. In this phase I/II study, we assessed nivolumab's safety in 92 ipilimumab-refractory patients with unresectable stage III or IV melanoma, including those who experienced grade...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Jeffrey S. Weber, Geoffrey T. Gibney, Ragini R. Kudchadkar, Bin Yu, Pingyan Cheng, Alberto J. Martinez, Jodie Kroeger, Allison Richards, Lori McCormick, Valerie E. Moberg, Heather Cronin, Xiuhua Zhao, Michael J. Schell, Y. Ann Chen
Format: Artigo
Langue:anglais
Publié: 2016
Accès en ligne:https://doi.org/10.1158/2326-6066.cir-15-0193
https://cancerimmunolres.aacrjournals.org/content/canimm/4/4/345.full.pdf
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Internet

https://doi.org/10.1158/2326-6066.cir-15-0193
https://cancerimmunolres.aacrjournals.org/content/canimm/4/4/345.full.pdf

Documents similaires